Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
about
Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential PracticesThe PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral DrugsA Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.AASLD guidelines for treatment of chronic hepatitis B.Bone health in HIV-infected children, adolescents and young adults: a systematic review.Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.Bone health in HIV-infected children and adolescents.In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.PrEP as Peri-conception HIV Prevention for Women and Men.A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Disclosing in utero HIV/ARV exposure to the HIV-exposed uninfected adolescent: is it necessary?Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approachBone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Complications of Treatment in Youth with HIV.Impact of maternal HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health.Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus.Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelinesReply to Koo et alThird-trimester tenofovir to prevent mother-to-child hepatitis B virus transmission.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Hepatitis B in Pregnancy.Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.Ethical and Psychosocial Considerations in Informing HIV-Exposed Uninfected Children That They Were Exposed to HIV and Antiretroviral Medications In Utero.Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China.Current evidence on the management of hepatitis B in pregnancy
P2860
Q26738453-479B3374-79E7-46C0-89B4-55CADAF6C66DQ26744617-9A70A93F-F8E7-48B5-B4DD-D315EC28412CQ33711399-B508745B-1B9A-4C6F-BD0A-95D68FF9C2C5Q34501660-8CC4A22B-FAA5-4CCF-AD70-6DC9B96F6770Q35822412-4D1EAB35-01CB-4E74-9A03-0E3435D907B9Q35840548-D2C2F63B-BF78-49B8-B8D2-917D53DA72D2Q36882631-5042E84E-799C-4A24-A489-F651ACBC270EQ36948111-076D3BBA-9E68-4D9F-B4A4-B6A53DDEEB7AQ36963511-1DE1FCA6-94E5-489E-AAFA-35A6FCA9CE9BQ37277571-3241424B-195F-4A7D-A3B5-886B42E181C1Q37298218-38D6EEEE-9C87-4EC6-A2F0-0BF6BD16C7ADQ37342120-DD20B393-7FDD-4DB6-943B-8ED6ED02F9C3Q38609568-2B96AC2A-0653-49F9-B00D-56059743B22CQ38737364-00EFB175-781A-482D-83B8-FC7F65B62683Q38801873-04D74DE9-2C1D-449D-B5D6-450978844A1FQ38828635-A6A359D2-07AF-48AF-A89A-66904DBEB4A9Q38846571-FEC3361D-79C7-4761-94EA-4346B9DCAA9AQ38890564-6EC3994F-5166-413B-8959-300B72E45061Q38909409-06926485-DA49-4B76-8E5D-9F7F5943A32AQ39145435-36CFA0B5-8276-46C4-97E4-2B1F26C4330FQ39258357-B2144492-DCB3-4BE8-B05A-FABD3772DC94Q39520236-6518950B-820D-4776-9947-A1FC61DF6A41Q42334798-B557719B-4E81-441F-948E-656967A1BFE6Q42399337-38FDD6D5-16CD-4906-964F-4C75FFDA959BQ45073764-84BBD38E-D867-41A7-AB8B-6E2BCB7539CEQ50190669-4B66D012-9390-4CE9-8909-1C597C7910BAQ50859070-B9CD087D-A9E6-45C7-843C-C01AD96E0518Q52571189-8CDFDD1A-C7DD-4C42-B454-9F8CFD5C37D3Q54574017-D8D4DE90-B6A4-45BB-9DE2-ACC06A83F15DQ55711692-756EBD70-0248-4CBB-B3B6-0BEEBC5E5125Q57491228-900E9DCF-A82F-42F2-91D2-66C65527EA8C
P2860
Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@ast
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@en
type
label
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@ast
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@en
prefLabel
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@ast
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@en
P2093
P2860
P356
P1476
Lower Newborn Bone Mineral Con ...... xil Fumarate During Pregnancy.
@en
P2093
Denise L Jacobson
Emily Barr
George K Siberry
George R Seage
Heidi J Kalkwarf
Julia W Wu
Justin J Wheeler
Katherine M Knapp
Kenneth C Rich
Laurie Butler
P2860
P304
P356
10.1093/CID/CIV437
P407
P577
2015-06-09T00:00:00Z